The Global Drug sales of Entyvio stood at USD 6,449.02 Millions in 2022
The indicator recorded a historical growth (CAGR) of26% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Vedolizumab (Entyvio) is a humanized monoclonal antibody produced in Chinese hamster ovary cells. It is formulated as lyophilized powder for concentrate for solution for intravenous route (infusion) and solution for subcutaneous route of administration.
Mechanism of Action
Vedolizumab selectively binds and inhibits alpha4beta7 integrin, which inhibits the binding between alpha4beta7 integrin and MadCAM-1(mucosal adhesion molecule 1) existing mainly in the intestinal mucosa. Integrins are a type of cell surface protein, its main roles are cellular binding to the extracellular matrix and signal transduction from the extracellular matrix. Expression of beta7 has mainly been studied on lymphocytes whereas macrophages have been reported not to express the beta7 integrins. Integrins are trans-membrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM).
Entyvio Overview
Entyvio is marketed for several indications in Entyvio Gastrointestinal, Immunology, Infectious Disease, and Oncology therapy areas.
Entyvio is indicated for in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids, in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
Entyvio was first approved in 2014 and is sold globally including the US, the UK, France, Germany, and Japan by Takeda Pharmaceutical Co Ltd and its subsidiaries. Entyvio drug sales recorded a low-double digit Year on Year growth in 2022. Entyvio drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward